KRAS and ovarian carcinoma: Similar associations between the proportion of RAS (KRAS, NRAS) or BRAF mutations in mutant PIK3CA and wtPIK3CA, although not always statistically significant, were found in disease-specific subanalysis in colorectal cancer (14/18 [78%] vs. 42/86 [49%]; p = 0.04), ovarian cancer (5/7 [71%] vs. 2/43 [5%]; p<0.001), and all tested cancers excluding colorectal (10/33 [30%] vs. 52/299 [17%]; p = 0.1) (Figure 3B–D).We also analyzed the frequency of PIK3CA mutations in patients with mutant RAS (KRAS, NRAS) or BRAF compared to patients without RAS (KRAS, NRAS) or BRAF mutations.